TransMedics Group

TMDX on Nasdaq. TransMedics sells organ preservation machines and transplant services to hospitals. Market value $3.2bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
1.5%low

For every $100 of what the whole company costs, it produced $1.51 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 44 of 100. Price score: 52 of 100. Our list needs 70 on quality and 60 on price.

$85.25 a share, 42% above its 1-year low

Over the past year the price has ranged from $60.10 to $156.00.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.1
-0.2
-0.1
0.1
0.0
2021202220232024202512 monthsto Sep '26

Spare cash swings from quarter to quarter here: $45 million in the past 12 months, $134 million in the year to December 2025.

Revenue
$30m$93m$242m$442m$605m
Operating margin
-130.3%-33.6%-11.9%8.5%17.9%
Debt to equity
0.520.31n/an/an/a
Shares outstanding
0.03bn0.03bn0.03bn0.03bn0.03bn

Health checks

  • Free cash flow positive1 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)6 of 8 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsStrong, 88.2% a year
  • Buying back its own sharesNo, 9% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $203 million last quarter, up 41% on a year ago.
  • Profit: $17 million, down 30% on a year ago.
  • It keeps 12 cents of each $1 of sales as operating profit, down from 17 cents a year earlier.
  • Spare cash over the past 12 months: $45 million, down from $121 million.
  • About the same number of shares as a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$122m
March 2025$144m
June 2025$157m
September 2025$144m
December 2025$161m
March 2026$174m
June 2026$190m
September 2026$203m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024$7m
March 2025$26m
June 2025$35m
September 2025$24m
December 2025$105m
March 2026$7m
June 2026$15m
September 2026$17m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
24 February 2026
Next quarterly (estimated, 10-Q)
4 February 2027

Who owns it

None of the long-term investors we follow own it. 374 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $109,058 of shares on the open market. 7 sold $5m.

  • TOBIN JAMES R
    Director
    Sold
    Date
    9 November 2026
    Shares
    4,059
    Price
    $94.97
    Value
    $385,464
  • Weill David
    Director
    Bought
    Date
    11 September 2026
    Shares
    1,336
    Price
    $81.63
    Value
    $109,058
  • Gunderson Thomas J.
    Director
    Sold
    Date
    15 June 2026
    Shares
    9,624
    Price
    $75.06
    Value
    $722,377
  • Lovell Stephanie
    Director
    Sold
    Date
    4 March 2026
    Shares
    1,193
    Price
    $149.62
    Value
    $178,497
  • Weill David
    Director
    Sold
    Date
    4 March 2026
    Shares
    3,571
    Price
    $146.82
    Value
    $524,294
  • Hernandez Gerardo
    Chief Financial Officer
    Sold
    Date
    4 March 2026
    Shares
    7,236
    Price
    $147.21
    Value
    $1m
  • Hernandez Gerardo
    Chief Financial Officer
    Sold
    Date
    2 March 2026
    Shares
    375
    Price
    $139.12
    Value
    $52,170
  • Ranganath Anil P.
    See remarks
    Sold
    Date
    2 March 2026
    Shares
    864
    Price
    $139.12
    Value
    $120,200
  • Corcoran Nicholas
    See remarks
    Sold
    Date
    2 March 2026
    Shares
    2,966
    Price
    $139.12
    Value
    $412,630
  • Hernandez Gerardo
    Chief Financial Officer
    Sold
    Date
    4 December 2025
    Shares
    920
    Price
    $139.62
    Value
    $128,450

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in TransMedics Group’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Feb 2026, plus the 10-Q filed 5 Nov 2026 and 6 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting.”
    Show the full paragraph
    Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting. Specifically, the Company has not designed and maintained effective controls over inventory movement within its manufacturing network. While effective controls are in place to verify the existence and accuracy of inventory as of year-end, effective controls have not been designed and maintained to verify that inventory movements are appropriately recorded in the interim financial statements. Notwithstanding the material weakness, and based on the additional analyses and other procedures management performed, we have concluded that our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial position and results of operations and cash flows as of each of the dates, and for each of the periods, presented therein in accordance with generally accepted accounting principles in the United States of America.

    From the 10-Q filed 5 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.